HAPPYMINI® IN THE HALLUX RIGIDUS The ISIAT 2019 held in Lisbon in October was the occasion for LABRHA to present a study about HAppyMini® in the Hallux Rigidus (Osteoarthritis of the first metatarso-phalangeal joint). This prospective open-label multicentre pilot trial was conducted on 65 patients and safety was very good Read more…
This prospective pilot study was conducted to show the Safety & Efficacy of a Single Injection of Mannitol-modified Cross-Linked Hyaluronic Acid (HAppyMini®) in the treatment of the Temporo-Mandibular Osteoartritis. Results at D180 : Treatment was efficient or very efficient for 94% of the patients Long lasting improvment of the inter-incisal distance 2/3 of patients reduced their painkillers Read more…
Like every year since 2012, LABRHA attended the EULAR Annual Meeting which took place in Amsterdam from the 13th to the 16th of June 2018. During the scientific session on “OSTEOARTHRITIS and microcrystalline disease”, Dr Thierry CONROZIER (France) presented results of the INSTINCT Study: influence of the radiological grade on the efficacy Read more…
The 4th edition of the International Symposium on Intra-Articular Treatment (ISIAT) took place in Prague last 5th to 7th of October 2017. Organized every two years across different European cities by Prof. Alberto Migliore (IT), this congress is, as its name suggests, focus on intra-articular management of joint disease including Read more…
Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Conrozier T. Curr Rheumatol Rev. 2017 Jul 10. doi:10.2174/1573397113666170710115558. Viscosupplementation with intra-articular injections of hyaluronic acid is recommended as a second line treatment for knee OA, after failure of non-pharmacological modalities and usual Read more…